Aravax
Latest round
- Series B
Last raised
- Jan 2024
Total raised
- $75M
Investors
- 8
About Aravax
Founded in 2015 in Melbourne, Australia, Aravax is dedicated to creating therapies for food allergies. The company has successfully completed Phase 1 clinical trials for its lead product and has commenced Phase 2 trials.Aravax is focused on developing innovative, disease-modifying treatments for food allergies, with its lead product, PVX108, specifically targeting peanut allergies. Utilizing a proprietary platform technology, Aravax aims to reset the immune system's response to allergens, promoting long-term tolerance without inducing severe allergic reactions during treatment. Following the successful completion of Phase 1 clinical trials, Phase 2 trials have commenced and are fully recruited in clinical sites across Australia and the United States. The primary end-users of these therapies include adolescents and children diagnosed with peanut allergies, as well as their families, healthcare providers, and allergists who seek effective solutions to manage food allergy conditions.Aravax's revenue generation model is based on the advancement and commercialization of its leading product, PVX108, through clinical trials and subsequent market entry. The primary transaction structure involves partnerships with healthcare institutions and clinical trial sites, where the firm conducts Phase 2 and future Phase 3 trials aimed at validating the safety and efficacy of its therapies. As these products progress through the clinical development stages, potential revenue streams are anticipated from licensing agreements, partnerships with pharmaceutical companies, and eventual sales to healthcare providers and patients. Given the specialized nature of the treatment, pricing strategies will likely reflect the high-value and novel therapeutic approaches Aravax is introducing to the food allergy domain. The company aims to launch its lead product, PVX108, in new markets, expanding its reach into North America and select regions in Australia.
Who invested in Aravax
8 investors across 2 rounds
See all investors in Aravax
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aravax
Who invested in Aravax?
Aravax has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aravax raised?
Aravax has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Aravax last raise money?
Aravax's most recent round on record is a Series B, in Jan 2024.
What does Aravax do?
Founded in 2015 in Melbourne, Australia, Aravax is dedicated to creating therapies for food allergies.
Where is Aravax headquartered?
Aravax is headquartered in Melbourne, Australia.
Which VCs invest in companies like Aravax?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Movac back biotechnology companies at Aravax's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Aravax? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.